EFFICACY AND SAFETY OF SIMVASTATIN IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL, CONTROLLED STUDY

Abstract. Recently discovered immune–modulating and anti-inflammatory properties of statins have resulted in application of these drugs for treatment of autoimmune disorders. There are few studies investigating therapeutic potential of simvastatin in rheumatoid arthritis (RA). In present study, we i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	I. V. Shirinsky, O. I. Zheltova, V. S. Shirinsky, V. A. Kozlov
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2014
Materias:	rheumatoid arthritis statins disease-modifying therapy Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/55940b68a245480db26b15e9de3f05ac
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:55940b68a245480db26b15e9de3f05ac
record_format	dspace
spelling	oai:doaj.org-article:55940b68a245480db26b15e9de3f05ac2021-11-18T08:03:39ZEFFICACY AND SAFETY OF SIMVASTATIN IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL, CONTROLLED STUDY1563-06252313-741X10.15789/1563-0625-2008-4-5-477-482https://doaj.org/article/55940b68a245480db26b15e9de3f05ac2014-07-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/227https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XAbstract. Recently discovered immune–modulating and anti-inflammatory properties of statins have resulted in application of these drugs for treatment of autoimmune disorders. There are few studies investigating therapeutic potential of simvastatin in rheumatoid arthritis (RA). In present study, we investigated efficacy and safety of simvastatin in active RA patients treated with conventional disease-modifying antirheumatic drugs (DMARDs). Thirty-three patients were enrolled into an open-label, controlled study. The patients received treatment with 40 mg of simvastatin daily for 12 weeks. A group of historical controls consisted of nine patients taking placebo combined with disease-modifying therapy. No differences in demographic characteristics and disease activity were observed between the two groups. By the end of therapy (12 weeks), simvastatin-treated patients exhibited a significant reduction in disease activity scores with 28-joint counts (DAS28), and according to physician’s assessment of disease, as compared with control group. The estimate of trea tment effect (DAS28 scores) was 0.76 (95% confidence interval 0.01-1.5), thus corresponding to moderate decrease in disease activity. In conclusion, combination therapy with simvastatin and conventional DMARDs results into decreased RA activity. However, additional studies are required in order to specify exact role of simvastatin in RA treatment. (Med. Immunol., vol. 10, N 4-5, pp 477-482).I. V. ShirinskyO. I. ZheltovaV. S. ShirinskyV. A. KozlovSPb RAACIarticlerheumatoid arthritisstatinsdisease-modifying therapyImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 10, Iss 4-5, Pp 477-482 (2014)
institution	DOAJ
collection	DOAJ
language	RU
topic	rheumatoid arthritis statins disease-modifying therapy Immunologic diseases. Allergy RC581-607
spellingShingle	rheumatoid arthritis statins disease-modifying therapy Immunologic diseases. Allergy RC581-607 I. V. Shirinsky O. I. Zheltova V. S. Shirinsky V. A. Kozlov EFFICACY AND SAFETY OF SIMVASTATIN IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL, CONTROLLED STUDY
description	Abstract. Recently discovered immune–modulating and anti-inflammatory properties of statins have resulted in application of these drugs for treatment of autoimmune disorders. There are few studies investigating therapeutic potential of simvastatin in rheumatoid arthritis (RA). In present study, we investigated efficacy and safety of simvastatin in active RA patients treated with conventional disease-modifying antirheumatic drugs (DMARDs). Thirty-three patients were enrolled into an open-label, controlled study. The patients received treatment with 40 mg of simvastatin daily for 12 weeks. A group of historical controls consisted of nine patients taking placebo combined with disease-modifying therapy. No differences in demographic characteristics and disease activity were observed between the two groups. By the end of therapy (12 weeks), simvastatin-treated patients exhibited a significant reduction in disease activity scores with 28-joint counts (DAS28), and according to physician’s assessment of disease, as compared with control group. The estimate of trea tment effect (DAS28 scores) was 0.76 (95% confidence interval 0.01-1.5), thus corresponding to moderate decrease in disease activity. In conclusion, combination therapy with simvastatin and conventional DMARDs results into decreased RA activity. However, additional studies are required in order to specify exact role of simvastatin in RA treatment. (Med. Immunol., vol. 10, N 4-5, pp 477-482).
format	article
author	I. V. Shirinsky O. I. Zheltova V. S. Shirinsky V. A. Kozlov
author_facet	I. V. Shirinsky O. I. Zheltova V. S. Shirinsky V. A. Kozlov
author_sort	I. V. Shirinsky
title	EFFICACY AND SAFETY OF SIMVASTATIN IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL, CONTROLLED STUDY
title_short	EFFICACY AND SAFETY OF SIMVASTATIN IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL, CONTROLLED STUDY
title_full	EFFICACY AND SAFETY OF SIMVASTATIN IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL, CONTROLLED STUDY
title_fullStr	EFFICACY AND SAFETY OF SIMVASTATIN IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL, CONTROLLED STUDY
title_full_unstemmed	EFFICACY AND SAFETY OF SIMVASTATIN IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL, CONTROLLED STUDY
title_sort	efficacy and safety of simvastatin in rheumatoid arthritis: an open-label, controlled study
publisher	SPb RAACI
publishDate	2014
url	https://doaj.org/article/55940b68a245480db26b15e9de3f05ac
work_keys_str_mv	AT ivshirinsky efficacyandsafetyofsimvastatininrheumatoidarthritisanopenlabelcontrolledstudy AT oizheltova efficacyandsafetyofsimvastatininrheumatoidarthritisanopenlabelcontrolledstudy AT vsshirinsky efficacyandsafetyofsimvastatininrheumatoidarthritisanopenlabelcontrolledstudy AT vakozlov efficacyandsafetyofsimvastatininrheumatoidarthritisanopenlabelcontrolledstudy
_version_	1718422544378232832

EFFICACY AND SAFETY OF SIMVASTATIN IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL, CONTROLLED STUDY

Ejemplares similares